FY2028 Earnings Estimate for TPST Issued By William Blair

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Equities researchers at William Blair issued their FY2028 earnings estimates for Tempest Therapeutics in a research report issued on Thursday, March 27th. William Blair analyst M. Phipps expects that the company will post earnings per share of ($1.60) for the year. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share.

A number of other brokerages have also recently issued reports on TPST. Scotiabank dropped their price target on shares of Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating on the stock in a research note on Friday. HC Wainwright dropped their target price on shares of Tempest Therapeutics from $47.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday.

Tempest Therapeutics Trading Down 8.1 %

NASDAQ TPST opened at $0.77 on Monday. Tempest Therapeutics has a 12 month low of $0.70 and a 12 month high of $6.00. The stock’s fifty day moving average price is $0.87 and its 200-day moving average price is $0.97. The stock has a market cap of $33.70 million, a P/E ratio of -0.50 and a beta of -1.83.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.07). The company had revenue of $0.49 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in shares of Tempest Therapeutics during the third quarter valued at $34,000. Geode Capital Management LLC lifted its stake in Tempest Therapeutics by 42.7% during the 3rd quarter. Geode Capital Management LLC now owns 220,067 shares of the company’s stock valued at $308,000 after acquiring an additional 65,826 shares during the period. Virtu Financial LLC purchased a new stake in shares of Tempest Therapeutics during the 4th quarter valued at about $36,000. Versant Venture Management LLC bought a new stake in shares of Tempest Therapeutics in the fourth quarter worth approximately $2,927,000. Finally, Northern Trust Corp raised its holdings in shares of Tempest Therapeutics by 233.2% during the fourth quarter. Northern Trust Corp now owns 67,815 shares of the company’s stock valued at $57,000 after purchasing an additional 47,461 shares during the last quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.